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Summary
During biosynthesis of the anthracycline antitumor
agents daunomycin, adriamycin, and aclacinomycin,
the polyketide-derived tetracyclic aglycone is enzy-
matically glycosylated at the C7-OH by dedicated
glycosyltransferases (Gtfs) that transfer L-2,3,6-tri-
deoxy-3-aminohexoses. In aclacinomycins, the first
deoxyhexose is predicted to be transferred via AknS
action, then subjected to further elongation to a tri-
saccharide by the subsequent Gtf, AknK. We report
here that purified AknS has very low activity in the
absence of the adjacently encoded AknT; however, at
a 3:1 ratio, AknT stimulates AknS kcat by 40-fold up to
0.22 min−1 for transfer of L-2-deoxyfucose (2-dF) to
the aglycone aklavinone. It is likely that several other
Gtfs that glycosylate polyketide aglycones also act
as two-component catalytic systems. Incubations of
purified AknS/AknT/AknK with two aglycones and two
dTDP-2-deoxyhexoses produced previously unchar-
acterized anthracycline disaccharides.
Introduction
The anthracycline class of natural products has proven
to be comprised of useful antitumor agents in combina-
tion chemotherapy regimens [1, 2]. These include dau-
nomycin 1 and adriamycin 2 as well as aclacinomycin A
3 (Figure 1). The anthracycline drugs have a tetracyclic
aromatic polyketide planar scaffold that is enzymati-
cally tailored at the C7-OH by L-aminodeoxy sugars. In
daunomycin 1 and adriamycin 2, the monosaccharide
L-2,3,6-trideoxy-3-aminohexose, known as daunosam-
ine (Dau), is attached by the enzyme DnrS from the
dTDP-L-daunosamine [1–3]. In aclacinomycin A, the
sugar enzymatically tethered to the aglycone core is
N,N-dimethyl-daunosamine, known as L-rhodosamine.
In turn, an L-2-deoxyfucose (2-dF) is connected to the
C4 oxygen of the rhodosamine; attachment of cineru-
lose to the C4 oxygen of the 2-dF residue completes
the trisaccharide chain of aclacinomycin A [1, 4, 5].
The deoxysugar moieties in the anthracycline drugs
are not just solubilizing groups. Structural studies of
drug-DNA complexes have shown that the sugars bind*Correspondence: christopher_walsh@hms.harvard.eduto the minor groove region of target DNA sequences
[6–8]. Therefore, there has been interest in manipulation
of the deoxysugars, not just at the monosaccharide
level, but also to control identity and length of oligosac-
charide chains [9–12]. To this end, we and others have
been interested in characterization of the catalytic ac-
tivity and the possible promiscuity of the glycosyl
transferases (Gtfs) in anthracycline tailoring. For exam-
ple, we have recently reported that AknK in the aclaci-
nomycin biosynthetic pathway is the Gtf transferring
the second L-deoxyhexose, 2-dF, onto the rhodosami-
nyl-aklavinone intermediate [13].
Full manipulation of the entire oligosaccharide chain
of aclacinomycin requires the first Gtf, presumptively
encoded by AknS [4], a homolog to the single Gtf DnrS
from the daunomycin biosynthetic pathway [3]. In our
hands, DnrS expressed heterologously in E. coli has
shown folding defects, and it has not yet been resolubi-
lized into active form. By contrast, AknS, when overpro-
duced in E. coli, is soluble; however, in initial studies, it
had shown minute activity with aklavinone and several
dTDP-L-aminodeoxyhexoses (data not shown). A re-
cent paper from Hung-Wen Liu and colleagues on Des-
VII, the desosaminyl transferase that decorates the
macrolactone core in pikromycin biosynthesis, shows
that DesVII is active only when the upstream gene en-
coding DesVIII is present [14]. Similarly, in the aclacino-
mycin A biosynthetic gene cluster, a desVIII homolog,
aknT, is adjacent to aknS [4].
In this paper, we report the expression and purifica-
tion of AknS and AknT, and we show that AknT is the
required partner protein to activate AknS for its antici-
pated Gtf activity on the aklavinone substrate. These
findings suggest a general strategy of two-component
Gtfs in polyketide scaffold glycosylations. With a com-
bination of AknS/AknT and AknK, we generate four new
anthracycline diglycosides, indicating that these an-
thracycline Gtfs are useful enzymes for the chemoenzy-
matic synthesis of anthracycline glycoside variants.
Results
Expression and Purification of AknS and AknT
The biosynthetic gene clusters for aclacinomycin A in
the producing strain Streptomyces galilaeus gene clus-
ter contain two proposed Gtf genes, aknS and aknK [4,
5]. By virtue of homology to DnrS, AknS is proposed to
catalyze the transfer of the proximal deoxyhexose,
L-rhodosamine, from an NDP-rhodosamine to the C7-
OH of the tetracyclic scaffold. A highly relevant recent
finding by the Liu group is that DesVII, the aglycone-
modifying Gtf in pikromycin biosynthesis, is active only
when adjacently upstream DesVIII is presented [14]. In
this context, aknT, a desVIII homolog, is also located
immediately upstream of aknS. To study whether AknT
is required for the activity of AknS, both S. galileus
genes were subcloned into pET-22b expression vectors
and expressed in E. coli as soluble C-terminal, His6-
tagged proteins. Upon purification by Ni-NTA affinity
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(A) Chemical structures of anthracycline nat-
ural products.
(B) Scheme of a partial aclacinomycin A bio-
synthesis gene cluster.chromatography, both proteins were obtained in the w
usoluble form and in greater than 95% purity based on
SDS-PAGE analysis (data not shown). The overall yield c
cfor each protein was 20 mg per liter culture.
s
fAknT Is Required for the Full Activity of AknS
AIt is anticipated that during the biosynthesis of aclaci-
mnomycin A, AknS uses dTDP-L-rhodosamine as the au-
rthentic donor for transfer of the first deoxyhexose to
Ithe C7-OH of aklavinone. However, the nucleosidedi-
tphospho L-2,3,6 trideoxy-3-dimethylamino sugar, dTDP-
grhodosamine, is not available to study the activity of
cAknS. The first alternative substrate assayed was dTDP-
L-daunosamine (the di-desmethyl analog of dTDP-rho-
mdosamine) [13]. While the AknS activity was detected,
fit was less than 0.01 min−1, even in the presence of
vAknT. The low activity could be due to the fact that the
synthetic dTDP-L-daunosamine was a mixture of α and
β anomers at the C1# of the aminosugar and that the α
anomer could be inhibitory; this issue remains to be B
aexamined in the future.
Several anthracycline natural variants use 2-deoxyfu- T
ucose as the proximal sugar [12, 15, 16], and we have
recently reported the synthesis of the pure β form of t
mdTDP-2-deoxyfucose for the characterization of AknK.
We used dTDP-2-deoxyfucose as an alternative donor t
csubstrate to survey the activity of AknS. With aklavi-
none and dTDP-2-deoxyfucose as cosubstrates, AknS [
salone was indeed active (Figures 2A and B). AknS con-
verted less than 10% of 100 M aklavinone to 2-deoxy- S
tfucosyl-aklavinone in 120 min, as analyzed by RP-
HPLC and confirmed by MALDI ([M-H]−: calculated, w
541.5; observed, 542.0). Under the same conditions,
AknT converted no aklavinone to the deoxyfucosylated A
iaglycone product. In contrast, in the presence of AknT,
AknS converts over 60% of 100 M aklavinone to the w
oanthracycline monoglycoside under the same condi-
tions. Examination of the time course of AknS alone i
sand the AknS + AknT combination showed that the
presence of AknT stimulated AknS activity by at least c
t40-fold (Figure 2C).
Since AknT has an activating effect on AknS activity, i
ethe dependence of AknS activity on the concentration
of AknT was examined (Figure 3). At three concentra- o
btions of AknS (2.5, 5, and 10 M), saturation behavioras observed for AknS activity in the ranges of AknT
sed. The apparent Km for AknT varied with the AknS
oncentration at 7.2, 17.2, and 31.2 M, for the indi-
ated three concentrations of AknS, respectively. This
uggested that in the 2.5–10 M range, AknS and AknT
unction optimally when the molar ratio is 1:3
knS:AknT. The apparent Km values for AknT in the
icromolar range are consistent with a specific but
eadily reversible interaction between AknS and AknT.
n agreement, gel filtration analysis was unable to de-
ect a stable complex between AknS and AknT, sug-
esting a high Kd for the complex under the reaction
ondition.
At 2.5 M AknS and 60 M AknT, the kcat is 0.22
in−1 for 2-dF transfer, a 40-fold rate enhancement
rom the estimated 0.005 min−1 for AknS alone. The Km
alues for aklavinone and dTDP-2-deoxyfucose are 3.5
M and 287 M, respectively (Figure 5B).
inding Measurement between Aklavinone
nd AknS/AknT with Fluorescence Titration
he observation that AknT stimulates AknS activity led
s to investigate the role that AknT plays during activa-
ion. AknT could enhance AknS activity by at least three
echanisms: 1) AknT could serve as a regulatory pro-
ein to control/increase the activity of AknS; 2) AknT
ould be a chaperone protein, as suggested for DesVIII
14]; and 3) AknT could bind the hydrophobic aglycone
ubstrate and present it to the active site of AknS.
ince aklavinone itself is fluorescent, we investigated
he interaction of either protein alone or in combination
ith the aglycone by fluorescence spectroscopy.
When AknS, AknT, or a combination of AknS and
knT was titrated into 2.5 M aklavinone, the change
n fluorescence emission at 598 nm shown in Figure 4
as observed. AknS clearly binds aklavinone, and a Kd
f 5.6 M was calculated by fitting to a single binding
sotherm. AknT had no effect, even at 60 M (data not
hown). When levels of AknT (40 M) that saturate the
atalytic activity were added to aklavinone and AknS,
he Kd dropped approximately 50-fold to 100 nM. This
ncrease in affinity for aklavinone is close to the 40-fold
ffect seen on kcat, suggesting that the activating effect
f AknT on glycosyl transfer is correlated with tighter
inding of the aglycone substrate. No fluorescence
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529Figure 2. AknS/AknT Complex Transfers
2-Deoxyfucose from dTDP-2-Deoxyfucose
to Aklavinone 4 to Give 2-Deoxyfucosyl-
Aklavinone 5
(A) Chemical equation for conversion of 4 to
5 by AknS/AknT.
(B) Comparison of conversion of 4 to 5 cata-
lyzed by 50 M AknS, 50 M AknT, or 10 M
AknS + 40 M AknT. In each reaction, 100
M aklavinone was used, and each reaction
was maintained at 25°C for 120 min. The re-
actions were analyzed by RP-HPLC.
(C) Time course of conversion of 4 (100 M
initial) to 5 catalyzed by 50 M AknS (■), 50
M AknT (,), or 10 M AknS + 40 M
AknT (C).nose, has been synthesized (unpublished data). When
Figure 3. The Dependence of AknS Activity on AknT
The activity of 2.5 M (>), 5 M (,), and 10 M (B) AknS was
determined with up to 80 M AknT with aklavinone and dTDP-
2-deoxyfucose as substrates. The data were fitted to the Michaelis-
Menten equation to give an apparent K for AknT.quenching of the authentic AknS/AknT product L-rho-
dosaminyl-aklavinone was detected with AknS alone,
AknT alone, or the AknS/AknT combinations (data not
shown), suggesting that the tetracyclic scaffold in the
product is bound less tightly or in a different microenvi-
ronment.
The Two-Component AknS/AknT Transfer Other
L-2-deoxysugars to C7-OH of Aklavinone
Beside dTDP-2-deoxyfucose, the AknS/AknT complex
also transfers other 2-deoxyhexoses to aklavinone. For
studies in glycopeptide Gtfs, the 4-amino regioisomer
of dTDP-daunosamine, dTDP-4-amino-2-deoxyrham-mdTDP-4-amino-2-deoxyrhamnose was used as an al-
ternate sugar donor, the AknS activity was measured
with 2.5 M Gtf and 60 M AknT (Figure 5). AknS
transfers 4-amino-2-deoxyrhamnose to aklavinone to
make compound 9, ([M+H]+: calculated, 542.5; ob-
served, 542.3) with a kcat of 0.17 min−1. The Km values
for aklavinone and the sugar donor were 3.1 M and
407 M, respectively. These catalytic efficiencies, do-
minated by the low kcat, are comparable to those seen
with 2-dF transfer.
AknS Transfers L-2-deoxyfucose to an Alternate
Aglycone Scaffold
-Rhodomycinone 6 is the tetracyclic aglycone that is
enzymatically tailored at the comparable C7-OH posi-
tion in the daunomycin biosynthetic pathway [2]. This
aglycone contains a hydroxyl at the C10 position that is
absent in aklavinone (Figure 5). 5 M AknS, in the pres-
ence of 60 M AknT, was able to transfer 2-deoxy-
fucose to -rhodomycinone 6 to make 2-deoxyfucosyl-
-rhodomycinone 7 ([M-H]−: calculated, 557.5; observed,
558.0) with a kcat of 0.086 min−1, half that of the authen-
tic aglycone. The Km values for -rhodomycinone and
dTDP-2-deoxyfucose are 46 M and 156 M, respec-
tively. The Km value of -rhodomycinone is >10-fold ele-
vated with this aglycone, but determination of the full
kinetic mechanism is required before this can be de-
convoluted into molecular events.
Generation of Novel Anthracycline Disaccharides
by Sequential Actions of AknS/AknT and AknK
We recently reported that AknK transfers 2-deoxysu-
gars to the axial 4#-OH of anthracycline monosaccha-
rides, such as daunomycin, adriamycin, and idarubicin,
to generate anthracycline disaccharides [13]. With the
successful enzymatic generation of several anthracy-
cline monoglycosides by the AknS/AknT complex, it
Chemistry & Biology
530Figure 4. AknT Facilitates the Binding of
AknS to Aklavinone
(A) Determination of binding between AknS
and aklavinone. 2.5 M aklavinone was ti-
trated with up to 48 M AknS. The fluores-
cence emission at 598 nm was plotted, and
the data were fitted to the binding isotherm
as described in the Experimental Proce-
dures.
(B) Determination of binding between AknS
and aklavinone in the presence of AknT. 2.5
M aklavinone and 40 M AknT were pre-
mixed before AknS was introduced.axial 4#-OH of the 2,6-dideoxyhexose attached to an 
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aFigure 5. Kinetic Analysis of AknS/AknT Activity
[(A) Chemical equations of the AknS/AknT-catalyzed reaction.
m(B) Kinetic data of the AknS/AknT-catalyzed reaction. Reactions
were performed in triplicate. twas possible to evaluate enzymatic tailoring of the a
taglycones to anthracycline diglycosides by tandem ac-
tion of AknS/AknT and AknK. n
AIn the first case, AknS/AknT was used to transfer
2-deoxyfucose from dTDP-2-deoxyfucose to aklavi- d
gnone 4 to make 2-deoxyfucosyl-aklavinone 5 (Figure 6).
AknK was then used to transfer a second 2-deoxy- (
rfucose to a portion of compound 5 to generate
2-deoxyfucosyl-2-deoxyfucosyl-aklavinone 10 ([M+Na]+: a
dcalculated, 695.7; measured, 695.4). Although full struc-
ture determination of this disaccharide has not been
tundertaken, the known regioselectivity of AknK for thenthracycline aglycone strongly favors 10 as the struc-
ure of the 2dF-2dF-aklavinone, which is found in the
atural product isolated from the H054 mutant [15].
knK was also used to transfer L-daunosamine from
TDP-L-daunosamine to the AknS/AknT product 5 to
enerate daunosaminyl-2-deoxyfucosyl-aklavinone 12
[M+H]+: calculated, 672.7; observed, 672.5). This is the
everse regioisomer of the 2-deoxyfucosyl-2-daunos-
minyl-aklavinone that has previously made from
TDP-daunosamine, dTDP-2dF, and AknK [13].
Analogously, the AknS/AknT complex was used to
ransfer 2-deoxyfucose to the alternate aglycone,
-rhodomycinone 6, to generate 2-deoxyfucosyl--rho-
omycinone 7, followed by AknK transfer of 2-deoxyfu-
ose to make 2-deoxyfucosyl-2-deoxyfucosyl--rhodo-
ycinone 11 ([M-H]−: calculated, 687.7; observed,
88.2). AknK was also used to transfer daunosamine to
ompound 7 to make daunosaminyl-2-deoxyfucosyl--
hodomycinone 13 ([M+H]+: calculated, 688.7; ob-
erved, 688.7). In the course of generating these -rho-
omycinone-containing mono- or disaccharides, there
ere shoulders that immediately followed the main
eaks; however, these shoulders contained the same
olecular weight as the main peaks. The identities of
he species in these chromatographic shoulders are to
e determined.
iscussion
he AknS protein from S. galileus, overexpressed in
. coli, is soluble and readily purified as a His6-tagged
usion protein. This is in contrast to its insoluble homo-
og DnrS from the daunomycin producer, which is not
oluble when expressed in E. coli. To assay AknS for
he anticipated aglycone C7-OH glycosyltransferase
ctivity, the aglycone, aklavinone, and the anticipated
TDP-L-deoxyhexose are required. The sugar is most
robably rhodosamine, although the timing of N-meth-
lation is not known with certainty. dTDP-L-daunosa-
ine could be the substrate produced by N,N-dimethy-
ation after glycosylation.
The authentic aglycone, aklavinone, is available by
cid hydrolysis of the natural product aclacinomycin A
17]. The physiologic donor substrate dTDP-rhodosa-
ine has not been made synthetically. We found that
he AknS exhibited very low activity when using dTDP-
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Glycosides by Sequential Actions of AknS/
AknT and AknK
(A) Scheme for conversion of anthracycline
aglycones (aklavinone 4 or -rhodomycinone
6) to four anthracycline diglycosides (10–13)
by tandem action of AknS/AknT (with dTDP-
2-deoxyfucose) and AknK (dTDP-2-deoxyfu-
cose or dTDP-daunosamine).
(B) HPLC traces of the reaction mixtures dur-
ing each step as indicated.L-daunosamine as a substrate, even in the presence
of AknT.
dTDP-2-deoxyfucose was used to examine the AknS
activity in light of the fact that several anthracyclines
have this deoxyhexose as the proximal sugar. More-
over, this sugar is available and has been used for the
next enzyme, AknK [13].
Indeed, with dTDP-2-dF as the hexosyl donor, AknS
has very low but real activity whose kinetics can be
followed, yielding a kcat value of about 0.005 min−1 in
the absence of its partner protein, AknT. When purified
AknT is present, the activity of AknS is elevated 40-fold
to a kcat of 0.22 min−1. The Km value for dTDP-2-dF
is 288 M, consistent with good recognition, and the
aklavinone Km is around 3 M. AknS activity, even after
having been stimulated by AknT by 40-fold, is still one
to two orders of magnitude lower than other glyco-
syltransferases, such as AknK and NovM [13, 18]. An
equivalent kcat of 0.17 min−1 was seen for L-4-amino-2-
deoxyrhamnosyl transfer. This low Gtf activity could be
attributed to the usage of alternate NDP-sugar donors,
and the determination of kcat and Km values must wait
for pure dTDP-rhodosamine β anomer to become
available.
At this juncture, it is clear that AknT is a saturable
activator for the AknS catalytic subunit. One might have
expected AknS and AknT to form a tight, nondissocia-
ble subunit pair, but that is not the case since these
two proteins can be expressed separately or together
in E. coli. AknT does show saturation behavior at three
different AknS concentrations (2.5, 5, and 10 M). AknT
saturates at about a 3:1 molar ratio of T/S. This is initial
evidence of specificity but suggests a high enough Kd
that, under the reaction conditions described for AknS/
AknT complex, the two proteins are in rapid reversible
equilibrium with the monomers. Gel filtration also did
not detect any stable heterooligomer formation.
The exact role of AknT or the AknT homologs in other
two-component Gtfs noted below is not yet clear. AknT
could be operating as a regulatory subunit to controlthe active conformation of AknS in its role as a Gtf. This
could be akin to the role of cyclin subunits in cyclin-
activated protein kinases. The 40-fold activation of
basal AknS Gtf activity by AknT is consistent with such
an activating role. This 40-fold effect is paralleled by a
50-fold increase in the affinity of AknS for the aglycone
in the presence of AknT.
AknS has high homology to other microbial glyco-
syltransferases, for which the three-dimensional struc-
tures have been solved [19, 20]. These Gtfs contain two
domains: one domain binds the NDP-hexose donor, the
other binds the acceptor cosubstrate. The aglycone is
often a hydrophobic molecule and is accordingly rec-
ognized by a pocket lined with many hydrophobic side
chains in that region of the active site in the Gtf [19].
We think it highly likely that AknS will adopt this two-
domain architecture and that quenching of fluores-
cence of aklavinone reflects its binding in a hydropho-
bic subsite. AknT binding to AknS may optimize the fit
and productive orientation of aklavinone in this part of
the active site of AknS, improving catalytic efficiency.
Qasba and coworkers have shown a similar phenome-
non in the glycosyltransferase B-1-4-Gal-T1 [21]. They
found that the addition of α-lacatalbumin changes the
substrate specificity of B-1,4-Gal-T1 from N-acetylglu-
cosamine to glucose.
Additionally or alternatively, AknT could have a chap-
erone role, as suggested for DesVIII [14]. But AknS, ex-
pressed on its own, folds to a soluble protein, has low
levels of activity, and is immediately activated when
AknT is added, as though refolding cycles are not in-
volved. AknT, DesVIII, and other homologs have signifi-
cant sequence homology to apo forms of cytochrome
P450s but lack the conserved Cys that is an axial thio-
late ligand to heme. In sum, further kinetic and struc-
tural studies of the AknS/AknT complex will be required
to delineate the mode of activation of the basal AknS
activity by AknT.
One of the motivations for examining the role of AknT
as a potential activator/chaperone for AknS was the re-
Chemistry & Biology
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mhomolog DesVIII for activity [14]. In that initial study, no
kinetic or binding characterization of the DesVII/DesVIII f
tpair was reported; thus, the AknS/AknT results reported
here also set a baseline for further examination of the b
DesVII/VIII interaction. It seems unlikely that DesVIII
Ewas acting as a chaperone for DesVII in the incubations
described. However, EryCIII, a homolog of DesVII in er-
Mythronolide scaffold tailoring, seems to require chaper-
T
one assistance to achieve activity on expression in E
E. coli [22]. p
tBorisova et al. noted that homologs of DesVIII are
falso found adjacent to Gtfs in two other macrolide tai-
ploring pathways, the erythromycin pathway (EryCII) and
pthe tylosin pathway (TylMIII), suggesting a general reli-
f
ance on a two protein complex for the first glycosyla- c
tion step on those polyketide aglycones. They also pre-
dicted DnrQ [3] as a potential partner to DnrS in the P
Taromatic polyketide anthracycline daunomycin, and
athat is exactly parallel to the AknS/AknT system de-
lscribed here.
CIt may be that enzymatic tailoring of OH groups via
G
glycosylation on hydrophobic polyketide aglycones, in F
both macrolide and aromatic tetracyclic frameworks, T
Ghave evolved two-component Gtfs. As a practical
amatter, one should assay these polyketide Gtfs as two-
bcomponent systems to see if in vitro activity is thereby
treconstituted to set up enzymatic approaches to alter-
i
native, regioselective glycosylations. f
Finally, the ability to generate active AknS, as the
AknS/AknT pair, allows us to begin conducting tandem E
BGtf reactions for the generation of oligosaccharide de-
trivatives of anthracyclines. In this regard, we could sup-
rply dTDP-L-2-deoxyfucose as donor substrates for
both the AknS/AknT complex and the next Gtf, AknK
P[13], to convert aklavinone to the 2-dF-2-dF-aklavinone
A
product 10. Under the incubation conditions, the chain m
elongation stopped at the disaccharide, even though c
(we have reported that AknK has low but real activity at
otwo cycles of elongation to generate the trisaccharyl-
aaklavinone [13]. Using the combination of AknS/AknT
r(with dTDP-L-2-deoxyfucose) and AknK (with dTDP-L-
t
daunosamine), we could generate the dau-2-dF-aklavi- w
none 12. We have recently used AknK with daunomycin v
and dTDP-2-dF to make the complementary disaccha-
ride tether (L-daunosaminyl-4,1-L-2-deoxyfucose) to C
Cthe related aglycone -rhodomycinone. The pair of Gtfs,
IAknS/AknT and AknK, will allow the generation of sev-
deral anthracyclines with scaffold as well as first and
b
second L-deoxysugars varied by enzymatic tailoring. 2
These could be made in quantities useful for cell-based o
sevaluation of antiumor properties, including assay for
ndecreased efflux and preferential double-strand cleav-
page of target DNA [23–25].
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Significance a
c
nAnthracyclines, such as aclacinomycin A and dauno-
imycin, are useful antitumor agents in combination
pwith other chemotherapeutic agents. These com-
fpounds consist of conserved tetracyclic scaffolds v
and diversified oligosaccharide chains ranging from
aone to three deoxysugars. Serving as a minor grooveinder of targeted DNA sequences, the carbohydrate
oieties are important pharmacophore determinants
or anthracyclines. The work described here opens
he way to generate anthracyline glycoside variants
y using enzymatic approaches.
xperimental Procedures
aterials
he pET-22b expression vector was purchased from Novagen.
. coli Top10 and BL21(DE3) chemically competent cells were
urchased from Invitrogen. Primers were purchased from In-
ergrated DNA Technologies. Pfu DNA polymerase was purchased
rom Stratagene. Restriction enzymes and T4 DNA ligase were
urchased from New England Biolabs. The Ni-NTA resin was
urchased from Qiagen. Fluorescence cuvettes were purchased
rom Starna Cells. Aclacinomycin A was purchased from Calbio-
hem.
lasmid Construction
he aknS and aknT genes were PCR amplified from pSgc4 plasmid,
gift from Dr. Sirke Torkkell and colleagues [4]. For aknS, the fol-
owing primer pairs were used: 5#-AAAAAACATATGCGGGTTCTC
TGACATCC-3# and 5#-AAAAAACTCGAGGGACACGCATGGCGAC
TACC-3#, in which NdeI and XhoI restriction sites are underlined.
or aknT, the following primer pairs were used: 5#-AAAAAACA
ATGCAGACACAGAACGCGCCG-3# and 5#-AAAAAAAAGCTTCGC
GAGGTGGTCAGGGGGAAGC-3#, in which NdeI and HindIII sites
re underlined. The aknS gene was cloned into the pET-22b vector
y using NdeI and XhoI sites, while the aknT gene was cloned into
he pET-22b vector by using NdeI and HindIII sites. The open read-
ng frames of both genes were confirmed by DNA sequencing be-
ore transforming into BL21(DE3) competent cells.
xpression and Purification of AknS and AknT
oth AknS and AknT proteins were expressed as C-terminal His6-
agged proteins in E. coli and were purified by Ni-NTA chromatog-
aphy by following the protocol previously described [13].
reparation of Aglycone and TDP Sugars
klavinone was prepared from commercially available aclacino-
ycin A by using 0.1 M HCl in dry methanol at 25°C for 12 hr. The
ompound was further purified with a Vydac semi-prep C18 column
0%–100% acetonitrile in 0.1% trifluoroacetic acid [TFA] in H2O
ver 20 min, 3 ml/min). The desired fractions, monitored at 435 nm
nd confirmed by LC-MS, were combined and lyophilized. The pu-
ity of aklavinone is greater than 95%. -rhodomycinone was ob-
ained as a gift from Dr. Sirke Torkkell (Galilaeus). The TDP sugars
ere synthesized by following the procedures published pre-
iously [13].
haracterization of the Glycosylation Reaction
atalyzed by AknS/AknT
n general, aglycones (aklavinone or -rhodomycinone) and TDP-L-
eoxysugars were incubated with AknT and AknS in 50 l reaction
uffer (75 mM Tris [pH 7.5], 10 mM MgCl2, and 10% [v/v] DMSO) at
5°C for 8–60 min unless otherwise mentioned. An aliquot (10 l)
f the reaction mixture was quenched with 90 l methanol. The
amples were centrifuged at 13,000 rpm for 2 min, and the super-
atants were analyzed by RP-HPLC by using a short Vydac protein/
eptide C18 column (30%–50% acetonitrile in 0.1% TFA in H2O over
min, 3 ml/min). The products were monitored at 435 or 490 nm,
espectively, when aklavinone or -rhodomycinone was used as the
glycone substrate. The molecular weights of the products were
onfirmed by MALDI-TOF. The peak areas for the anthracycline mo-
oglycoside products and the remaining aglycone substrates were
ntegrated, and the product concentration was deduced from its
ercentage of the total peak area. The initial velocity data were
itted to the Michaelis-Menten equation to obtain Km and kcat
alues.
To determine the kinetic parameters for AknS, 0.5–2.5 M AknS
nd 60 M AknT were included in each reaction. For the measure-
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533ment of the Km for the TDP-deoxysugar, 0–1600 M TDP-deoxy-
hexoses were used, while aglycone substrates were kept at 100
M. For the measurement of the Km for the aglycone, 1.5–200 M
aglycones were used, while TDP-deoxyhexoses were maintained
at 1600 M.
Generation of the Anthracycline Disaccharide by Tandem
Reaction of AknS/AKnT Followed by AknK
100 M aglycone substrate (aklavinone or -rhodomycinone) and
800 M TDP-2-deoxyfucose were incubated with 5 M AknS and
60 M AknT in 200 l of the reaction buffer mentioned above for 6
hr to obtain compound 5 or 7, respectively. 80 l of the resultant
mixtures was then incubated with 5 M AknK for 6 hr to obtain
compound 10 or 11. Another 80 l of the resultant reaction mixture
was incubated with 5 M AknK and 800 M TDP-daunosamine for
6 hr to obtain compound 12 or 13, respectively. The reaction mix-
tures from each step were analyzed by RP-HPLC by using a C18
small pore column (30%–70% acetonitrile in 0.1% TFA in H2O over
20 min, 1 ml/min). The molecular weights of the desired products
were confirmed by MALDI-TOF MS.
Measurement of Binding Constants by Fluorescence Titration
The fluorescence titration experiments were performed on a Pho-
ton Technology International fluorometer. Excitation and emission
slit widths were set to 10 nm. 2.5 M aklavinone dissolved in 150
l binding buffer (75 mM Tris [pH 7.5], 10 mM MgCl2, and 100 mM
NaCl) was excited at 500 nm. The emission spectrum was recorded
between 540 and 640 nm. To measure the binding between aklavi-
none and AknS or AknT individually, an aliquot of protein was
added and mixed thoroughly by pipetting before the emission
spectrum was recorded. To measure the binding between aklavi-
none and AknS in the presence of AknT, 40 M AknT was premixed
with 2.5 M aklavinone before AknS was added.
Changes in the fluorescence emission were monitored at 598 nm.
Emission intensity was corrected for volume dilution before data
analysis. The signal change versus final concentration of the pro-
tein was fitted into the following equation to obtain the Kd and the
effective aklavinone concentration:
,
in which F is the fluorescence change after AknS is added, F0 is
the total fluorescence quenching after excess AknS is added, [Aka]
is the aklavinone concentration, [AknS] is the concentration of
AknS, and Kd is the dissociation constant between aklavinone
and AknS.
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